Al-Ola Abdallah/LinkedIn
Jul 5, 2025, 13:32
Al-Ola A Abdallah: Why is Belantamab Mafodotin Called a “Trojan Horse” in Myeloma?
Al-Ola A Abdallah, Associate Professor and Plasma Cell Disorder Program Director of the Division of HMCT at the University of Kansas Medical Center, shared a post on X:
“NEWS: The FDA’s ODAC will meet on July 17, 2025, to review the belantamab mafodotin in combination regimens for RRMM
Why is Belantamab Mafodotin Called a “Trojan Horse” in Myeloma?
Belantamab mafodotin = an antibody–drug conjugate (ADC) targeting BCMA on myeloma cells.
But it’s more than just targeted therapy — it sneaks a toxin into the cell. Here’s how.
- Targeting: The antibody portion binds BCMA, a surface protein heavily expressed on myeloma cells.
- Internalization: The whole ADC is taken into the cell — much like the Trojan Horse being pulled into Troy.
- Payload delivery: Once inside, it releases MMAF, a cytotoxic agent that disrupts the cell’s microtubules, leading to apoptosis.
- Result:The Myeloma cell is killed from within, sparing surrounding healthy cells — just like soldiers hiding in the mythic horse.
- This “Trojan Horse” mechanism allows for precision cytotoxicity, especially valuable in relapsed/refractory cases where other therapies fail.
- Belantamab is making a comeback in combo therapies (e.g., with bortezomib or pomalidomide), showing OS and PFS benefits in new data.”
More posts featuring Al-Ola A Abdallah.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 5, 2025, 13:12
Jul 5, 2025, 13:07
Jul 5, 2025, 12:46
Jul 5, 2025, 12:24
Jul 5, 2025, 12:17